Evoke Pharma (EVOK) Competitors $4.31 +0.14 (+3.36%) As of 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends EVOK vs. EQ, DRRX, LPCN, NAII, ENLV, PLUR, NXTC, INAB, GOVX, and COCPShould you be buying Evoke Pharma stock or one of its competitors? The main competitors of Evoke Pharma include Equillium (EQ), DURECT (DRRX), Lipocine (LPCN), Natural Alternatives International (NAII), Enlivex Therapeutics (ENLV), Pluri (PLUR), NextCure (NXTC), IN8bio (INAB), GeoVax Labs (GOVX), and Cocrystal Pharma (COCP). These companies are all part of the "pharmaceutical products" industry. Evoke Pharma vs. Equillium DURECT Lipocine Natural Alternatives International Enlivex Therapeutics Pluri NextCure IN8bio GeoVax Labs Cocrystal Pharma Evoke Pharma (NASDAQ:EVOK) and Equillium (NASDAQ:EQ) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, earnings, valuation, community ranking, institutional ownership, analyst recommendations, dividends and risk. Does the media prefer EVOK or EQ? In the previous week, Evoke Pharma had 1 more articles in the media than Equillium. MarketBeat recorded 3 mentions for Evoke Pharma and 2 mentions for Equillium. Evoke Pharma's average media sentiment score of 1.19 beat Equillium's score of 0.92 indicating that Evoke Pharma is being referred to more favorably in the media. Company Overall Sentiment Evoke Pharma Positive Equillium Positive Do institutionals & insiders believe in EVOK or EQ? 27.0% of Equillium shares are held by institutional investors. 6.1% of Evoke Pharma shares are held by insiders. Comparatively, 30.3% of Equillium shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the MarketBeat Community prefer EVOK or EQ? Evoke Pharma received 324 more outperform votes than Equillium when rated by MarketBeat users. However, 83.72% of users gave Equillium an outperform vote while only 59.31% of users gave Evoke Pharma an outperform vote. CompanyUnderperformOutperformEvoke PharmaOutperform Votes36059.31% Underperform Votes24740.69% EquilliumOutperform Votes3683.72% Underperform Votes716.28% Which has preferable earnings & valuation, EVOK or EQ? Evoke Pharma has higher earnings, but lower revenue than Equillium. Equillium is trading at a lower price-to-earnings ratio than Evoke Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEvoke Pharma$8.62M0.74-$7.79M-$10.99-0.39Equillium$45.91M0.53-$13.34M-$0.14-4.92 Do analysts prefer EVOK or EQ? Equillium has a consensus target price of $5.00, suggesting a potential upside of 625.90%. Given Equillium's stronger consensus rating and higher possible upside, analysts plainly believe Equillium is more favorable than Evoke Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evoke Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Equillium 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, EVOK or EQ? Evoke Pharma has a beta of 0.15, indicating that its stock price is 85% less volatile than the S&P 500. Comparatively, Equillium has a beta of 1.78, indicating that its stock price is 78% more volatile than the S&P 500. Is EVOK or EQ more profitable? Equillium has a net margin of -10.05% compared to Evoke Pharma's net margin of -71.32%. Equillium's return on equity of -20.68% beat Evoke Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Evoke Pharma-71.32% -308.49% -53.66% Equillium -10.05%-20.68%-10.77% SummaryEquillium beats Evoke Pharma on 12 of the 18 factors compared between the two stocks. Get Evoke Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for EVOK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EVOK vs. The Competition Export to ExcelMetricEvoke PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.41M$6.54B$5.25B$8.80BDividend YieldN/A2.91%5.07%4.00%P/E Ratio-0.3910.2586.1216.98Price / Sales0.74176.191,077.10114.31Price / CashN/A57.6743.2137.77Price / Book-0.474.885.044.89Net Income-$7.79M$154.38M$122.32M$228.40M7 Day Performance-4.65%-8.12%-4.65%-3.68%1 Month Performance-8.49%-3.16%-0.99%0.03%1 Year Performance-52.11%-4.63%23.64%13.82% Evoke Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EVOKEvoke Pharma0.9043 of 5 stars$4.31+3.4%N/A-53.7%$6.41M$8.62M-0.394Short Interest ↓Positive NewsEQEquillium2.6746 of 5 stars$0.77-1.2%$5.00+552.1%-18.2%$27.17M$45.91M-5.4840Short Interest ↑DRRXDURECT4.1107 of 5 stars$0.87-0.5%$5.00+477.8%+25.4%$26.86M$8.59M-1.4280Analyst ForecastShort Interest ↓News CoveragePositive NewsLPCNLipocine2.7348 of 5 stars$5.00-1.2%$10.00+100.0%+32.3%$26.74M$7.92M-6.5810Short Interest ↓Positive NewsGap DownNAIINatural Alternatives International1.9882 of 5 stars$4.27-1.2%N/A-34.3%$26.47M$112.98M-2.97290Analyst ForecastNews CoveragePositive NewsENLVEnlivex Therapeutics3.7424 of 5 stars$1.23-1.6%$9.50+672.4%-59.9%$26.33MN/A-1.2670Short Interest ↓PLURPluri0.5936 of 5 stars$4.68+8.1%N/A-5.6%$26.02M$598,000.00-0.78150Short Interest ↑NXTCNextCure4.4633 of 5 stars$0.92+11.9%$4.00+334.8%-32.9%$25.77MN/A-0.4490Short Interest ↑News CoverageHigh Trading VolumeINABIN8bio3.9614 of 5 stars$0.35+19.4%$7.75+2,127.0%-79.1%$25.22MN/A-0.4620Short Interest ↓Positive NewsGap UpHigh Trading VolumeGOVXGeoVax Labs3.4119 of 5 stars$2.60-1.5%$14.20+446.2%-60.7%$24.53M$3.09M0.0017Short Interest ↓News CoveragePositive NewsCOCPCocrystal Pharma2.8969 of 5 stars$2.40+2.1%$7.00+191.7%+24.6%$24.42MN/A-1.3010Short Interest ↑News CoverageGap Up Related Companies and Tools Related Companies EQ Alternatives DRRX Alternatives LPCN Alternatives NAII Alternatives ENLV Alternatives PLUR Alternatives NXTC Alternatives INAB Alternatives GOVX Alternatives COCP Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:EVOK) was last updated on 1/14/2025 by MarketBeat.com Staff From Our PartnersStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredI was wrong. Dead wrong. Something is stirring deep in Silicon Valley. My team and I have been watching the tech markets closely. ...Porter & Company | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredDonald Trump is about to free crypto from its chains …With Donald Trump’s return to the oval office, the war on crypto is over. The digital currency is not only ...Weiss Ratings | SponsoredThe #1 Stock for Trump’s Second Term?Imagine how much money you could make if you bought all of the top performing stocks during Trump's second ter...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evoke Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evoke Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EVOK Stock Alerts